Arbutus to Present at Jefferies London Healthcare Conference

Rhea-AI Summary

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the Jefferies London Healthcare Conference. The company will conduct a fireside chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST. Investors can access the live webcast through the company's investor relations website, with an archived replay available for a time after the event.

News Market Reaction – ABUS

-0.55%

-0.55% Session move

In the trading session that priced this news, ABUS declined 0.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:

Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When is Arbutus Biopharma (ABUS) presenting at the Jefferies London Healthcare Conference 2024?

Arbutus Biopharma will present a fireside chat on November 21, 2024, at 12:00 pm GMT / 7:00 am EST at the Jefferies London Healthcare Conference.

How can investors watch Arbutus Biopharma's (ABUS) Jefferies Conference presentation?

Investors can watch the live webcast of the fireside chat by visiting https://investor.arbutusbio.com/events-presentations. An archived replay will be available on the website for a time after the event.

What is the main focus of Arbutus Biopharma's (ABUS) research?

Arbutus Biopharma focuses on developing a functional cure for chronic hepatitis B virus (cHBV) infection, leveraging their extensive virology expertise.